Engineered Cells for Cartilage Regeneration via Synthetic Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis lack disease-modifying therapies that can restore joint homeostasis, relying on surgical procedures and temporary drug administration due to limitations in small molecule and biologic therapies, which fail to sustainably regenerate cartilage and bone tissue.
Innovation Solution
Development of engineered cells with synthetic receptors capable of intramembrane proteolysis for spatiotemporally controlled expression of therapeutic transgenes, specifically designed to recognize cartilage damage and induce the production of anti-inflammatory and anabolic factors, such as IL-1Ra and TGF-β3, to promote cartilage and bone regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule or biologic drugs are administered to treat osteoarthritis, then pain is reduced and progression is ameliorated, but the drugs require repeat administration due to limited half-life in the intra-articular space
Solution Approach 1:
The engineered cells are designed to autonomously detect cartilage damage through synthetic receptors and self-regulate transgene expression in response to damage signals, eliminating the need for external drug administration and enabling sustained therapeutic effect without repeat dosing
Solution Approach 2:
The cells are pre-engineered with synthetic receptors and transgenes before administration, allowing them to immediately respond to cartilage damage signals and provide sustained therapeutic effect from the time of injection, avoiding the need for repeated administrations
2Productivity
If surgical procedures such as abrasion arthroplasty or microfracture are performed to encourage cell infiltration, then tissue regeneration is promoted, but outcomes decline after the initial post-operative period due to loss of chondrocyte phenotype and cell apoptosis
Solution Approach 1:
The engineered cells use synthetic receptors to continuously monitor cartilage damage and feedback-regulate transgene expression accordingly, ensuring sustained production of therapeutic factors that maintain chondrocyte phenotype and prevent apoptosis throughout the regenerative process
Solution Approach 2:
The cells dynamically adjust their therapeutic output by changing transgene expression levels in response to varying cartilage damage conditions, maintaining optimal regenerative function and preventing outcome decline over time
3Productivity
If progenitor or trophic cells are transplanted to restore joint function, then tissue synthesis is aided, but the tissue formed is fibrous rather than hyaline due to mismatch with physiologic demands
Solution Approach 1:
The engineered cells are designed to produce specific therapeutic transgenes (such as SOX9, RUNX2, or other chondroprotective factors) that locally promote hyaline cartilage formation rather than fibrous tissue, ensuring high-quality tissue matching the physiologic demands of the articular joint
Data Source
AI summary
The disclosure describes engineered cells for the treatment of joint and bone disease. The cells are engineered to sense signals only found in diseased compartments and in turn produce therapeutic molecules that are secreted into the local environment.